文献速递免疫规划传染病防控与疫情报告

重组五抗原金黄色葡萄球菌疫苗在闭合性骨折择期手术患者中的安全性与免疫原性:一项随机、双盲、安慰剂对照、多中心2期临床试验

The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial.
PubMed 文献 · Vaccine · 2023-07-27

在中国10个临床研究中心开展的随机双盲安慰剂对照2期试验中,348例18-70岁闭合性骨折择期手术患者按1:1随机接受rFSAV或安慰剂(第0天两剂、第7天一剂)。结果显示未发生3级局部不良事件,180天内总体全身不良事件发生率试验组40.24%与对照组33.72%无显著差异,抗原特异性结合抗体自第7天开始升高并于首次免疫后10-14天达峰,调理吞噬抗体也显著高于背景水平。

要点

  • rFSAV在闭合性骨折择期手术患者中安全且耐受性良好。
  • 首次免疫后180天内总体全身不良事件发生率试验组40.24% vs 对照组33.72%,无显著差异。
  • 抗原特异性结合抗体第7天开始升高,首次免疫后10-14天达峰,调理吞噬抗体显著高于背景水平。

核心结论

  • rFSAV在闭合性骨折择期手术患者中安全且耐受性良好,围手术期免疫程序可快速诱生强效特异性体液免疫应答,结果为进一步临床试验确认疫苗效力提供依据。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心2期临床试验,在中国10个临床研究中心开展,纳入18-70岁闭合性骨折择期手术患者348例,按1:1随机分配至rFSAV组(n=174)和安慰剂组(n=174),第0天接种两剂、第7天再接种一剂,研究期间所有参与者和研究者保持盲态。

主要发现

  • 未发生3级局部不良事件。
  • 首次免疫后180天内总体全身不良事件发生率试验组40.24% vs 对照组33.72%,无显著差异。
  • 抗原特异性结合抗体自第7天开始升高,首次免疫后10-14天达峰。
  • 快速且强效的调理吞噬抗体也显著高于背景水平。

关键数值与推荐

  • 安全性终点为180天内不良事件发生率。
  • 免疫原性终点包括接种后五种抗原特异性抗体水平及调理吞噬抗体。
  • 中国药物临床试验登记与信息公示平台注册号CTR20181788,WHO国际临床试验注册平台标识ChiCTR2200066259。

局限性

  • 原文结论指出这些结果为进一步临床试验确认疫苗效力提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccines are urgently required to control Staphylococcus aureus hospital and community infections and reduce the use of antibiotics. Here, we report the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in patients undergoing elective surgery for closed fractures. METHODS: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial was carried out in 10 clinical research centers in China. Patients undergoing elective surgery for closed fractures, aged 18-70 years, were randomly allocated at a ratio of 1:1 to receive the rFSAV or placebo at a regimen of two doses on day 0 and another dose on day 7. All participants and investigators remained blinded during the study period. The safety endpoint was the incidence of adverse events within 180 days. The immunogenicity endpoints included the level of specific antibodies to five antigens after vaccination, as well as opsonophagocytic antibodies. RESULTS: A total of 348 eligible participants were randomized to the rFSAV (n = 174) and placebo (n = 174) groups. No grade 3 local adverse events occurred. There was no significant difference in the incidence of overall systemic adverse events between the experimental (40.24 %) and control groups (33.72 %) within 180 days after the first immunization. The antigen-specific binding antibodies started to increase at days 7 and reached their peaks at 10-14 days after the first immunization. The rapid and potent opsonophagocytic antibodies were also substantially above the background levels. CONCLUSIONS: rFSAV is safe and well-tolerated in patients undergoing elective surgery for closed fractures. It elicited rapid and robust specific humoral immune responses using the perioperative immunization procedure. These results provide evidence for further clinical trials to confirm the vaccine efficacy. China's Drug Clinical Trials Registration and Information Publicity Platform registration number: CTR20181788. WHO International Clinical Trial Registry Platform identifier: ChiCTR2200066259.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jiang XY, Gong MQ, Zhang HJ, et al. The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial. Vaccine. 2023. PMID: 37516573. doi:10.1016/j.vaccine.2023.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。